PRECISION OPTICS CORPORATION 22 EAST BROADWAY GARDNER, MASSACHUSETTS 01440-3338 Telephone 978 / 630-1800 Telefax 978 / 630-1487 POC:26-0328 Page 1 of 1 NEWS RELEASE FOR IMMEDIATE RELEASE Wednesday

OPTICS CORPORATION ANNOUNCES

TO ITS SENIOR MANAGEMENT

Precision Optics Corporation, Inc. (OTC Bulletin Board: POCI.OB), ("Precision

Optics") today announced the appointment of Michael T. Pieniazek as Vice

President and Chief Financial Officer and Brian Spies as Director of Marketing.

They are expected to play key roles in Precision Optics' ongoing plans for

T. Pieniazek, Vice President and Chief Financial Officer, brings over

twenty-five years of broad international financial, operational and

administrative management experience having served in various senior executive

positions including President, Executive Vice President and Chief Financial

Officer at several publicly-traded medical device and biotechnology companies,

including, Equidyne Corporation, a California-based medical device company,

Organogenesis Inc. and Uromedical Diagnostic Inc. Mr. Pieniazek began his career

as an auditor with PriceWaterhouseCoopers LLP (formerly Coopers & Lybrand)

and is a graduate of Villanova University where he received a Bachelor of

Science in Accounting. Mr. Pieniazek has extensive experience in acquisitions,

managing corporate structure in growing organizations, and evaluation and

execution of debt and equity financing transactions.

Spies, Director of Marketing, brings 25 years of medical device experience

including Vice President of Marketing for Astra Tech, the dental implant

division of AstraZeneca, Global Team Leader of Digital OR and Visualization

Smith & Nephew Endoscopy, and Director of Geographic Expansion and Business

Development for Becton Dickinson Surgical Systems. Mr. Spies has an

undergraduate degree in Engineering from the University of Texas at Austin

an MBA from Columbia University in New York City. The addition of Mr. Spies

our staff is part of a broader strategy to pursue new markets for developing

products and to expand our leadership presence in endoscopic and minimally

invasive visualization.

believe these new broader skill sets in marketing, acquisitions, and financial

management will facilitate corporate growth commensurate with recent and ongoing

new product offerings in advanced medical instruments including

technology and new micro-precisionTM

Optics Corporation, a leading developer and manufacturer of advanced optical

instruments since 1982, designs and produces high-quality medical instruments,

optical thin film coatings, and other advanced optical systems. The Company's

medical instrumentation line includes laparoscopes, arthroscopes and

endocouplers and a world-class product line of 3-D endoscopes for use in

minimally invasive surgical procedures. The Company continues to advance

products through technical innovation, including development of: the next

generation (patent pending) of 3-D endoscopes; the extension of Lenslock

technology (patent pending) to its entire line of endoscopes; instrumentation

utilizing the Company's micro-precision lens technology (patent pending) for

optical components; assemblies and endoscopes under 1 mm. Precision Optics

Corporation is registered to ISO 9001:2000, ISO 13485:2003, and CMDCAS Quality

Standards, and complies with the FDA Good Manufacturing Practices and the

European Union Medical Device Directive for CE Marking of its medical products.

The Company's Internet Website is www.poci.com.

statements contained in this news release, including those related to the future

success of Company's newly released products and products under development are

made under "safe harbor" provisions of the Private Securities Litigation Reform

Act of 1995 and involve a number of risks and uncertainties that could

materially affect future results. These risks and uncertainties, many of which

are not within the Company's control, include, but are not limited to, the

uncertainty and timing of the successful development of the Company's new

products; decisions by customers to place orders for the Company's products; the

risks associated with reliance on a few key customers; the Company's ability to

attract and retain personnel with the necessary scientific and technical skills;

the timing and completion of significant orders; the timing and amount of the

Company's research and development expenditures; the timing and level of market

acceptance of customers' products for which the Company supplies components;

performance of the Company's vendors; the ability of the Company to control

costs associated with performance under fixed price contracts; the continued

availability to the Company of essential supplies, materials and services;

the other risk factors and cautionary statements listed from time to time in

Company's periodic reports filed with the Securities and Exchange Commission,

including but not limited to, the Company's Annual Report on Form 10-KSB for

year ended June 30, 2005 .